Putative neuroprotective agents in neuropsychiatric disorders

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 42, Issue , 2013, Pages 135-145

  Dodd, Seetal ^a,b   Maes, Michael ^a,d   Anderson, George ^e   Dean, Olivia M ^a,b   Moylan, Steven ^a   Berk, Michael ^a,b,c  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^d Piyavate Hospital   (Thailand)

^e CRC   (United Kingdom)

Author keywords

Antipsychotics; Melatonin; N acetyl cysteine; Statins

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ARIPIPRAZOLE; CLOZAPINE; DOCOSAHEXAENOIC ACID; ERYTHROPOIETIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LEPTIN; LINOLENIC ACID; LITHIUM; LURASIDONE; MELATONIN; MINOCYCLINE; NEUROPROTECTIVE AGENT; NORTRIPTYLINE; OLANZAPINE; PALIPERIDONE; PAROXETINE; PEROSPIRONE; PLACEBO; QUETIAPINE; REBOXETINE; ROSUVASTATIN; SALAZOSULFAPYRIDINE; SERTRALINE; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIPOLAR DISORDER; BRAIN ISCHEMIA; CLINICAL EFFECTIVENESS; COLITIS; COMORBIDITY; DEPRESSION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR DEPRESSION; MANIA; MENTAL HEALTH CARE; MOLECULAR PATHOLOGY; MOOD DISORDER; NERVE DEGENERATION; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROPSYCHIATRY; NEUROTOXICITY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; UPREGULATION;

ANIMALS; ASPIRIN; BIPOLAR DISORDER; DEPRESSIVE DISORDER; HUMANS; LITHIUM; MENTAL DISORDERS; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; SCHIZOPHRENIA;

EID: 84873523102     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.11.007     Document Type: Article

References (197)

1. Agartz I., Sedvall G.C., Terenius L., Kulle B., Frigessi A., Hall H., et al. BDNF gene variants and brain morphology in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:513-523.
2. Ahuja M., Bishnoi M., Chopra K. Protective effect of minocycline, a semi-synthetic second-generation tetracycline against 3-nitropropionic acid (3-NP)-induced neurotoxicity. Toxicology 2008, 244:111-122.
3. Ajith T.A., Riji T., Anu V. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin. Clin Exp Pharmacol Physiol 2008, 35:625-629.
4. Altamura A.C., Pozzoli S., Fiorentini A. Dell'Osso B. Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:63-70. (this issue).
5. Amminger G.P., Schafer M.R., Klier C.M., Slavik J.M., Holzer I., Holub M., et al. Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high-risk individuals. Mol Psychiatry 2012, 17:1150-1152.
6. Anderson G., Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis 2012, 27:113-119.
7. Anderson G., Maes M. Schizophrenia: Linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:5-19. (this issue).
8. Anderson G.A., Maes M., Berk M. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:101-114. (this issue).
9. Antonelli T., Ferraro L., Hillion J., Tomasini M.C., Rambert F.A., Fuxe K. Modafinil prevents glutamate cytotoxicity in cultured cortical neurons. Neuroreport 1998, 9:4209-4213.
10. Bai O., Chlan-Fourney J., Bowen R., Keegan D., Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003, 71:127-131.
11. Baker D.A., Xi Z.X., Shen H., Swanson C.J., Kalivas P.W. The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci 2002, 22:9134-9141.
12. Banks W.A. Role of the blood-brain barrier in the evolution of feeding and cognition. Ann N Y Acad Sci 2012, 1264:13-19.
13. Bechdolf A., Wood S.J., Nelson B., Velakoulis D., Yucel M., Takahashi T., et al. Amygdala and insula volumes prior to illness onset in bipolar disorder: a magnetic resonance imaging study. Psychiatry Res 2012, 201:34-39.
14. Berger G.E., Wood S.J., Ross M., Hamer C.A., Wellard R.M., Pell G., et al. Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. Curr Pharm Des 2012, 18:570-575.
15. Berk M., Dean O., Cotton S.M., Gama C.S., Kapczinski F., Fernandes B.S., et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 2011, 135:389-394.
16. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011, 35:804-817.
17. Berk M., Dean O.M., Cotton S.M., Gama C.S., Kapczinski F., Fernandes B., et al. Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomised placebo controlled trial. BMC Med 2012, 10:91.
18. Bian Q., Kato T., Monji A., Hashioka S., Mizoguchi Y., Horikawa H., et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:42-48.
19. Bora E., Fornito A., Yucel M., Pantelis C. Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder. Biol Psychiatry 2010, 67:1097-1105.
20. Bora E., Fornito A., Pantelis C., Yucel M. Gray matter abnormalities in major depressive disorder: a meta-analysis of voxel based morphometry studies. J Affect Disord 2011, 138:9-18.
21. Bora E., Fornito A., Yucel M., Bora E., Fornito A., Yucel M., et al. The effects of gender on grey matter abnormalities in major psychoses: a comparative voxelwise meta-analysis of schizophrenia and bipolar disorder. Psychol Med 2011, 1-13.
22. Bora E., Fornito A., Yucel M., Pantelis C. The effects of gender on grey matter abnormalities in major psychoses: a comparative voxelwise meta-analysis of schizophrenia and bipolar disorder. Psychol Med 2011, 1-13. [ePub ahead of press].
23. Bora E., Harrison B.J., Davey C.G., Yucel M., Pantelis C. Meta-analysis of volumetric abnormalities in cortico-striatal-pallidal-thalamic circuits in major depressive disorder. Psychol Med 2011, 1-11.
24. Brady R.O., Cooper A., Jensen J.E., Tandon N., Cohen B., Renshaw P., et al. A longitudinal pilot proton MRS investigation of the manic and euthymic states of bipolar disorder. Transl Psychiatry 2012, 2:e160.
25. Brunner R., Henze R., Parzer P., Kramer J., Feigl N., Lutz K., et al. Reduced prefrontal and orbitofrontal gray matter in female adolescents with borderline personality disorder: is it disorder specific?. Neuroimage 2010, 49:114-120.
26. Carrasco-Pozo C., Mizgier M.L., Speisky H., Gotteland M. Differential protective effects of quercetin, resveratrol, rutin and epigallocatechin gallate against mitochondrial dysfunction induced by indomethacin in Caco-2 cells. Chem Biol Interact 2012, 195:199-205.
27. Castro L.M., Gallant M., Niles L.P. Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells. J Neurochem 2005, 95:1227-1236.
28. Chalecka-Franaszek E., Chuang D.M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 1999, 96:8745-8750.
29. Charles M.S., Ostrowski R.P., Manaenko A., Duris K., Zhang J.H., Tang J. Role of the pituitary-adrenal axis in granulocyte-colony stimulating factor-induced neuroprotection against hypoxia-ischemia in neonatal rats. Neurobiol Dis 2012, 47:29-37.
30. Chaves C., De Marque C.R., Wichert-Ana L., Maia-De-Oliveira J.P., Itikawa E.N., Crippa J.A., et al. Functional neuroimaging of minocycline's effect in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:550-552.
31. Chen C.C., Huang T.L. Effects of antipsychotics on the serum BDNF levels in schizophrenia. Psychiatry Res 2011, 189:327-330.
32. Chen S.L., Lee S.Y., Chang Y.H., Chen S.H., Chu C.H., Tzeng N.S., et al. Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan. J Neuroimmune Pharmacol 2012, 7:656-664.
33. Chuang D.M., Wang Z., Chiu C.T. GSK-3 as a target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke. Front Mol Neurosci 2011, 4:15.
34. Chung Y.C., Kim S.R., Jin B.K. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 2010, 185:1230-1237.
35. Clay H.B., Sillivan S., Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci 2011, 29:311-324.
36. Cole J., Weinberger D.R., Mattay V.S., Cheng X., Toga A.W., Thompson P.M., et al. No effect of 5HTTLPR or BDNF Val66Met polymorphism on hippocampal morphology in major depression. Genes Brain Behav 2011, 10:756-764.
37. Condray R., Dougherty G.G., Keshavan M.S., Reddy R.D., Haas G.L., Montrose D.M., et al. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol 2011, 14:756-767.
38. Cui J., Shao L., Young L.T., Wang J.F. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 2007, 144:1447-1453.
39. De Sarno P., Axtell R.C., Raman C., Roth K.A., Alessi D.R., Jope R.S. Lithium prevents and ameliorates experimental autoimmune encephalomyelitis. J Immunol 2008, 181:338-345.
40. Dean B., Digney A., Sundram S., Thomas E., Scarr E. Plasma apolipoprotein E is decreased in schizophrenia spectrum and bipolar disorder. Psychiatry Res 2008, 158:75-78.
41. Dean O., Giorlando F., Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011, 36:78-86.
42. Dean O.M., Van Den Buuse M., Berk M., Copolov D.L., Mavros C., Bush A.I. N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder. Neurosci Lett 2011, 499:149-153.
43. Dean O.M., Data-Franco J., Giorlando F., Berk M. Minocycline: therapeutic potential in psychiatry. CNS Drugs 2012, 26:391-401.
44. Deng H., Fang Y. Aspirin metabolites are GPR35 agonists. Naunyn Schmiedebergs Arch Pharmacol 2012, 385(7):729-737. [Jul, Epub 2012 Apr 15].
45. Dhandapani K.M., Wade F.M., Wakade C., Mahesh V.B., Brann D.W. Neuroprotection by stem cell factor in rat cortical neurons involves AKT and NFkappaB. J Neurochem 2005, 95:9-19.
46. Dietrich M.O., Spuch C., Antequera D., Rodal I., De Yebenes J.G., Molina J.A., et al. Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol Aging 2008, 29:902-912.
47. Dodd S., Dean O., Copolov D.L., Malhi G.S., Berk M. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 2008, 8:1955-1962.
48. Drzyzga L., Obuchowicz E., Marcinowska A., Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 2006, 20:532-545.
49. Ehrenreich H., Degner D., Meller J., Brines M., Behe M., Hasselblatt M., et al. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry 2004, 9:42-54.
50. Fathali N., Lekic T., Zhang J.H., Tang J. Long-term evaluation of granulocyte-colony stimulating factor on hypoxic-ischemic brain damage in infant rats. Intensive Care Med 2010, 36:1602-1608.
51. Fattal O., Link J., Quinn K., Cohen B.H., Franco K. Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. CNS Spectr 2007, 12:429-438.
52. Ferreira A.P., Pasin J.S., Saraiva A.L., Ratzlaff V., Rossato M.F., Andrighetto R., et al. N-acetylcysteine prevents baker's-yeast-induced inflammation and fever. Inflamm Res 2012, 61:103-112.
53. Finsterer J. Treatment of mitochondrial disorders. Eur J Paediatr Neurol 2010, 14:29-44.
54. Flaum M. Strategies to close the "mortality gap". Am J Psychiatry 2010, 167:120-121.
55. Fond G., Macgregor A., Attal J., Larue A., Brittner M., Ducasse D., et al. Treating patients with schizophrenia deficit with erythropoietin?. Psychiatry Clin Neurosci 2012, 66:375-382.
56. Fontenelle L.F., Harrison B.J., Yucel M., Pujol J., Fujiwara H., Pantelis C. Is there evidence of brain white-matter abnormalities in obsessive-compulsive disorder? A narrative review. Top Magn Reson Imaging 2009, 20:291-298.
57. Fornito A., Yucel M., Wood S.J., Adamson C., Velakoulis D., Saling M.M., et al. Surface-based morphometry of the anterior cingulate cortex in first episode schizophrenia. Hum Brain Mapp 2008, 29:478-489.
58. Frommberger U.H., Bauer J., Haselbauer P., Fraulin A., Riemann D., Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997, 247:228-233.
59. Fumagalli F., Calabrese F., Luoni A., Bolis F., Racagni G., Riva M.A. Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. Int J Neuropsychopharmacol 2012, 15:235-246.
60. Fusar-Poli P., Berger G. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J Clin Psychopharmacol 2012, 32:179-185.
61. Galecki P., Szemraj J., Bienkiewicz M., Zboralski K., Galecka E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 2009, 24:277-286.
62. Garcia-Martinez E.M., Sanz-Blasco S., Karachitos A., Bandez M.J., Fernandez-Gomez F.J., Perez-Alvarez S., et al. Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells. Biochem Pharmacol 2010, 79:239-250.
63. Garner S.E., Eady E.A., Popescu C., Newton J., Li W.A. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev, CD002086 2003.
64. Garver D.L., Holcomb J.A., Christensen J.D. Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia. Int J Neuropsychopharmacol 2008, 11:49-61.
65. Gawryluk J.W., Wang J.F., Andreazza A.C., Shao L., Young L.T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011, 14:123-130.
66. Goldstein B.I., Collinger K.A., Lotrich F., Marsland A.L., Gill M.K., Axelson D.A., et al. Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. J Child Adolesc Psychopharmacol 2011, 21:479-484.
67. Gomez-Garcia A., Martinez Torres G., Ortega-Pierres L.E., Rodriguez-Ayala E., Alvarez-Aguilar C. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia. Rev Esp Cardiol 2007, 60:1242-1249.
68. Gonul A.S., Kitis O., Eker M.C., Eker O.D., Ozan E., Coburn K. Association of the brain-derived neurotrophic factor Val66Met polymorphism with hippocampus volumes in drug-free depressed patients. World J Biol Psychiatry 2011, 12:110-118.
69. Gray N.A., Zhou R., Du J., Moore G.J., Manji H.K. The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. J Clin Psychiatry 2003, 64(Suppl. 5):3-17.
70. Grillo R.W., Ottoni G.L., Leke R., Souza D.O., Portela L.V., Lara D.R. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 2007, 41:31-35.
71. Gupta B.B., Yanthan L., Singh K.M. In vitro effects of 5-hydroxytryptophan, indoleamines and leptin on arylalkylamine N-acetyltransferase (AA-NAT) activity in pineal organ of the fish, Clarias gariepinus (Burchell, 1822) during different phases of the breeding cycle. Indian J Exp Biol 2010, 48:786-792.
72. Gwag B.J., Lee Y.A., Ko S.Y., Lee M.J., Im D.S., Yun B.S., et al. Marked prevention of ischemic brain injury by Neu 2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine. J Cereb Blood Flow Metab 2007, 27:1142-1151.
73. Habibi J., Whaley-Connell A., Qazi M.A., Hayden M.R., Cooper S.A., Tramontano A., et al. Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology 2007, 148:2181-2188.
74. Hanssens L., De Hert M., Kalnicka D., Van Winkel R., Wampers M., Van Eyck D., et al. Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. Int Clin Psychopharmacol 2007, 22:43-49.
75. Hashimoto K. Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia?. CNS Neurol Disord Drug Targets 2009, 8:470-474.
76. Hashioka S., Klegeris A., Monji A., Kato T., Sawada M., Mcgeer P.L., et al. Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol 2007, 206:33-42.
77. Hodgson R.E., Mendis S. Lithium enabling use of clozapine in a patient with pre-existing neutropenia. Br J Hosp Med (Lond.) 2010, 71:535.
78. Homsi S., Federico F., Croci N., Palmier B., Plotkine M., Marchand-Leroux C., et al. Minocycline effects on cerebral edema: relations with inflammatory and oxidative stress markers following traumatic brain injury in mice. Brain Res 2009, 1291:122-132.
79. Hroudova J., Fisar Z. Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neuro Endocrinol Lett 2010, 31:336-342.
80. Hu X., Zhou H., Zhang D., Yang S., Qian L., Wu H.M., et al. Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation. J Neuroimmune Pharmacol 2012, 7:187-201.
81. Huang Y.Y., Peng C.H., Yang Y.P., Wu C.C., Hsu W.M., Wang H.J., et al. Desipramine activated Bcl-2 expression and inhibited lipopolysaccharide-induced apoptosis in hippocampus-derived adult neural stem cells. J Pharmacol Sci 2007, 104:61-72.
82. Hulshoff Pol H.E., Kahn R.S. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull 2008, 34:354-366.
83. Igue R., Potvin S., Bah R., Stip E., Bouchard R.H., Lipp O., et al. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1695-1698.
84. Jang S.W., Liu X., Pradoldej S., Tosini G., Chang Q., Iuvone P.M., et al. N-acetylserotonin activates TrkB receptor in a circadian rhythm. Proc Natl Acad Sci U S A 2010, 107:3876-3881.
85. Jin Y., Lim C.M., Kim S.W., Park J.Y., Seo J.S., Han P.L., et al. Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. Brain Res 2009, 1281:108-116.
86. Kato T., Mizoguchi Y., Monji A., Horikawa H., Suzuki S.O., Seki Y., et al. Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. J Neurochem 2008, 106:815-825.
87. Kaushal N., Elliott M., Robson M.J., Iyer A.K., Rojanasakul Y., Coop A., et al. AC927, a sigma receptor ligand, blocks methamphetamine-induced release of dopamine and generation of reactive oxygen species in NG108-15 cells. Mol Pharmacol 2012, 81:299-308.
88. Kernt M., Neubauer A.S., Eibl K.H., Wolf A., Ulbig M.W., Kampik A., et al. Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2. Clin Ophthalmol 2010, 4:591-604.
89. Khatibi N.H., Jadhav V., Saidi M., Chen W., Martin R., Stier G., et al. Granulocyte colony-stimulating factor treatment provides neuroprotection in surgically induced brain injured mice. Acta Neurochir Suppl 2011, 111:265-269.
90. Kim S.S., Kong P.J., Kim B.S., Sheen D.H., Nam S.Y., Chun W. Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch Pharm Res 2004, 27:314-318.
91. Kim Y.S., Ahn Y., Hong M.H., Kim K.H., Park H.W., Hong Y.J., et al. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells. J Cardiovasc Pharmacol 2007, 49:376-383.
92. Kim D.W., Kim D.S., Kim M.J., Kwon S.W., Ahn E.H., Jeong H.J., et al. Imipramine enhances neuroprotective effect of PEP-1-Catalase against ischemic neuronal damage. BMB Rep 2011, 44:647-652.
93. Knijff E.M., Breunis M.N., Kupka R.W., De Wit H.J., Ruwhof C., Akkerhuis G.W., et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord 2007, 9:743-753.
94. Koprivica V., Regardie K., Wolff C., Fernalld R., Murphy J.J., Kambayashi J., et al. Aripiprazole protects cortical neurons from glutamate toxicity. Eur J Pharmacol 2011, 651:73-76.
95. Kubera M., Obuchowicz E., Goehler L., Brzeszcz J., Maes M. In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:744-759.
96. Kuo P.H., Kao C.F., Chen P.Y., Chen C.H., Tsai Y.S., Lu M.L., et al. Polymorphisms of INSIG2, MC4R, and LEP are associated with obesity- and metabolic-related traits in schizophrenic patients. J Clin Psychopharmacol 2011, 31:705-711.
97. Kwak B., Mulhaupt F., Veillard N., Pelli G., Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 2001, 131:41-46.
98. Lauritzen I., Blondeau N., Heurteaux C., Widmann C., Romey G., Lazdunski M. Polyunsaturated fatty acids are potent neuroprotectors. EMBO J 2000, 19:1784-1793.
99. Lauterbach E.C., Shillcutt S.D., Victoroff J., Coburn K.L., Mendez M.F. Psychopharmacological neuroprotection in neurodegenerative disease: heuristic clinical applications. J Neuropsychiatry Clin Neurosci 2010, 22:130-154.
100. Lee J.E., Park J.H., Shin I.C., Koh H.C. Reactive oxygen species regulated mitochondria-mediated apoptosis in PC12 cells exposed to chlorpyrifos. Toxicol Appl Pharmacol 2012, 263:148-162.
101. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012, 36:764-785.
102. Levine J., Cholestoy A., Zimmerman J. Possible antidepressant effect of minocycline. Am J Psychiatry 1996, 153:582.
103. Levkovitz Y., Mendlovich S., Riwkes S., Braw Y., Levkovitch-Verbin H., Gal G., et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010, 71:138-149.
104. Lim C.M., Kim S.W., Park J.Y., Kim C., Yoon S.H., Lee J.K. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res 2009, 87:1037-1045.
105. Link A., Ayadhi T., Bohm M., Nickenig G. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 2006, 27:2945-2955.
106. Lipowski Z.J. Somatization and depression. Psychosomatics 1990, 31:13-21.
107. Lu X.H., Bradley R.J., Dwyer D.S. Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Res 2004, 1011:58-68.
108. Lu L.X., Guo S.Q., Chen W., Li Q., Cheng J., Guo J.H. Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia. Di Yi Jun Yi Da Xue Xue Bao 2004, 24:1251-1254.
109. Lv J., Du C., Wei W., Wu Z., Zhao G., Li Z., Xie X. The antiepileptic drug valproic Acid restores T cell homeostasis and ameliorates pathogenesis of experimental autoimmune encephalomyelitis. J Biol Chem 2012, 287:28656-28665.
110. Maes M., Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res 2012, 196:243-249.
111. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994, 89:346-351.
112. Maes M., Bosmans E., Kenis G., De Jong R., Smith R.S., Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 1997, 26:221-225.
113. Maes M., Delange J., Ranjan R., Meltzer H.Y., Desnyder R., Cooremans W., et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 1997, 66:1-11.
114. Maes M., Song C., Lin A.H., Pioli R., Kenis G., Kubera M., et al. In vitro immunoregulatory effects of lithium in healthy volunteers. Psychopharmacology (Berl) 1999, 143:401-407.
115. Maes M., Bocchio Chiavetto L., Bignotti S., Battisa Tura G.J., Pioli R., Boin F., et al. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 2002, 54:281-291.
116. Maes M., Galecki P., Chang Y.S., Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:676-692.
117. Maes M., Fišar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012, 20:127-150.
118. Martin V., Sainz R.M., Antolin I., Mayo J.C., Herrera F., Rodriguez C. Several antioxidant pathways are involved in astrocyte protection by melatonin. J Pineal Res 2002, 33:204-212.
119. Maurer I.C., Schippel P., Volz H.P. Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord 2009, 11:515-522.
120. Mayer C., Gruber H.J., Landl E.M., Pailer S., Scharnagl H., Truschnig-Wilders M., et al. Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Int J Clin Pharmacol Ther 2007, 45:319-327.
121. Menon R.R., Barta P.E., Aylward E.H., Richards S.S., Vaughn D.D., Tien A.Y., et al. Posterior superior temporal gyrus in schizophrenia: grey matter changes and clinical correlates. Schizophr Res 1995, 16:127-135.
122. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011, 70:663-671.
123. Miskowiak K.W., Vinberg M., Harmer C.J., Ehrenreich H., Kessing L.V. Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology (Berl) 2012, 219:687-698.
124. Mitchell A.J., Lord O. Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis. J Psychopharmacol 2010, 24:69-80.
125. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:304-307.
126. Miyaoka T., Yasukawa R., Yasuda H., Hayashida M., Inagaki T., Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol 2008, 31:287-292.
127. Miyaoka T., Wake R., Furuya M., Liaury K., Ieda M., Kawakami K., et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2012, 37:222-226.
128. Moncrieff J., Leo J. A systematic review of the effects of antipsychotic drugs on brain volume. Psychol Med 2010, 40:1409-1422.
129. Monji A., Kato T.A., Mizoguchi Y., Horikawa H., Seki Y., Kasai M., et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:115-121. (this issue).
130. Monteleone P., Natale M., La Rocca A., Maj M. Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. Neuropsychobiology 1997, 36:159-163.
131. Moore G.J., Bebchuk J.M., Hasanat K., Chen G., Seraji-Bozorgzad N., Wilds I.B., et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?. Biol Psychiatry 2000, 48:1-8.
132. Moroni F., Cozzi A., Sili M., Mannaioni G. Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm 2012, 119:133-139.
133. Moylan S., Maes M., Wray N.R., Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2012, [Epub ahead of print]. 10.1038/mp.2012.33.
134. Muller N., Myint A.M., Schwarz M.J. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects. Curr Pharm Des 2011, 17:130-136.
135. Myint A.M., Schwarz M.J., Verkerk R., Mueller H.H., Zach J., Scharpe S., et al. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav Immun 2011, 25:1576-1581.
136. Nierenberg AA, Kansky C, Brennan BP, Shelton RC, Perlis R, Iosifescu DV. Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development. Aust N Z J Psychiatry in press, [Electronic publication ahead of print].
137. Noel J., Zimmermann K., Busserolles J., Deval E., Alloui A., Diochot S., et al. The mechano-activated K+ channels TRAAK and TREK-1 control both warm and cold perception. EMBO J 2009, 28:1308-1318.
138. Orio L., Llopis N., Torres E., Izco M., O'Shea E., Colado M.I. A study on the mechanisms by which minocycline protects against MDMA ('ecstasy')-induced neurotoxicity of 5-HT cortical neurons. Neurotox Res 2010, 18:187-199.
139. Pabreja K., Dua K., Sharma S., Padi S.S., Kulkarni S.K. Minocycline attenuates the development of diabetic neuropathic pain: possible anti-inflammatory and anti-oxidant mechanisms. Eur J Pharmacol 2011, 661:15-21.
140. Pae C.U., Yoon C.H., Kim T.S., Kim J.J., Park S.H., Lee C.U., et al. Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. Int Immunopharmacol 2006, 6:666-671.
141. Pantelis C., Velakoulis D., Mcgorry P.D., Wood S.J., Suckling J., Phillips L.J., et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003, 361:281-288.
142. Park S.W., Lee J.G., Ha E.K., Choi S.M., Cho H.Y., Seo M.K., et al. Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells. Eur Neuropsychopharmacol 2009, 19:356-362.
143. Park S.W., Phuong V.T., Lee C.H., Lee J.G., Seo M.K., Cho H.Y., et al. Effects of antipsychotic drugs on BDNF, GSK-3beta, and beta-catenin expression in rats subjected to immobilization stress. Neurosci Res 2011, 71:335-340.
144. Pasco J.A., Jacka F.N., Williams L.J., Henry M.J., Nicholson G.C., Kotowicz M.A., et al. Leptin in depressed women: cross-sectional and longitudinal data from an epidemiologic study. J Affect Disord 2008, 107:221-225.
145. Paul-Clark M.J., Van Cao T., Moradi-Bidhendi N., Cooper D., Gilroy D.W. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med 2004, 200:69-78.
146. Pedrini M., Chendo I., Grande I., Lobato M.I., Belmonte-De-Abreu P.S., Lersch C., et al. Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. Neurosci Lett 2011, 491:207-210.
147. Peng C.H., Chiou S.H., Chen S.J., Chou Y.C., Ku H.H., Cheng C.K., et al. Neuroprotection by Imipramine against lipopolysaccharide-induced apoptosis in hippocampus-derived neural stem cells mediated by activation of BDNF and the MAPK pathway. Eur Neuropsychopharmacol 2008, 18:128-140.
148. Peng Q., Masuda N., Jiang M., Li Q., Zhao M., Ross C.A., et al. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp Neurol 2008, 210:154-163.
149. Politi P, RocchettiM, Emanuele E, RondanelliM, Barale F. Randomized Placebo-Controlled Trials of Omega-3 Polyunsaturated Fatty Acids in Psychiatric Disorders: a Review of Current Literature. Curr Drug Discov Technol in press, [Electronic publication ahead of print].
150. Prince J.A., Yassin M.S., Oreland L. Neuroleptic-induced mitochondrial enzyme alterations in the rat brain. J Pharmacol Exp Ther 1997, 280:261-267.
151. Qian H.R., Yang Y. Neuron differentiation and neuritogenesis stimulated by N-acetylcysteine (NAC). Acta Pharmacol Sin 2009, 30:907-912.
152. Raskind M.A., Burke B.L., Crites N.J., Tapp A.M., Rasmussen D.D. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology 2007, 32:284-288.
153. Rios-Lugo M.J., Cano P., Jimenez-Ortega V., Fernandez-Mateos M.P., Scacchi P.A., Cardinali D.P., et al. Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerides and cholesterol in normal and high fat-fed rats. J Pineal Res 2010, 49:342-348.
154. Ritsner M. The attribution of somatization in schizophrenia patients: a naturalistic follow-up study. J Clin Psychiatry 2003, 64:1370-1378.
155. Rodriguez C.I., Bender J., Marcus S.M., Snape M., Rynn M., Simpson H.B. Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial. J Clin Psychiatry 2010, 71:1247-1249.
156. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998, 279:1643-1650.
157. Sanches M., Keshavan M.S., Brambilla P., Soares J.C. Neurodevelopmental basis of bipolar disorder: a critical appraisal. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1617-1627.
158. Sarris J., Mischoulon D., Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry 2012, 73:81-86.
159. Sassi R.B., Nicoletti M., Brambilla P., Mallinger A.G., Frank E., Kupfer D.J., et al. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett 2002, 329:243-245.
160. Sassi R.B., Brambilla P., Hatch J.P., Nicoletti M.A., Mallinger A.G., Frank E., et al. Reduced left anterior cingulate volumes in untreated bipolar patients. Biol Psychiatry 2004, 56:467-475.
161. Schildknecht S., Pape R., Muller N., Robotta M., Marquardt A., Burkle A., et al. Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. J Biol Chem 2010, 286:4991-5002.
162. Schupp N., Schmid U., Heidland A., Stopper H. Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. Atherosclerosis 2008, 199:278-287.
163. Sheng R., Zhang L.S., Han R., Gao B., Liu X.Q., Qin Z.H. Combined prostaglandin E1 and lithium exert potent neuroprotection in a rat model of cerebral ischemia. Acta Pharmacol Sin 2011, 32:303-310.
164. Sicard P., Delemasure S., Korandji C., Segueira-Le Grand A., Lauzier B., Guilland J.C., et al. Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats. Free Radic Res 2008, 42:226-236.
165. Sierra S., Ramos M.C., Molina P., Esteo C., Vazquez J.A., Burgos J.S. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 2011, 23:307-318.
166. Silva R., Mesquita A.R., Bessa J., Sousa J.C., Sotiropoulos I., Leao P., et al. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta. Neuroscience 2008, 152:656-669.
167. Sironi L., Gianazza E., Gelosa P., Guerrini U., Nobili E., Gianella A., et al. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arterioscler Thromb Vasc Biol 2005, 25:598-603.
168. Sofuoglu M., Waters A.J., Mooney M., O'Malley S.S. Minocycline reduced craving for cigarettes but did not affect smoking or intravenous nicotine responses in humans. Pharmacol Biochem Behav 2009, 92:135-140.
169. Song C., Lin A., Kenis G., Bosmans E., Maes M. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr Res 2000, 42:157-164.
170. Strakowski S.M., Delbello M.P., Zimmerman M.E., Getz G.E., Mills N.P., Ret J., et al. Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. Am J Psychiatry 2002, 159:1841-1847.
171. Takahashi T., Wood S.J., Soulsby B., Mcgorry P.D., Tanino R., Suzuki M., et al. Follow-up MRI study of the insular cortex in first-episode psychosis and chronic schizophrenia. Schizophr Res 2009, 108:49-56.
172. Taler M., Gil-Ad I., Lomnitski L., Korov I., Baharav E., Bar M., et al. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol 2007, 17:774-780.
173. Taler M., Bar M., Korob I., Lomnitski L., Baharav E., Grunbaum-Novak N., et al. Evidence for an inhibitory immunomodulatory effect of selected antidepressants on rat splenocytes: possible relevance to depression and hyperactive-immune disorders. Int Immunopharmacol 2008, 8:526-533.
174. Tanibuchi Y., Shimagami M., Fukami G., Sekine Y., Iyo M., Hashimoto K. A case of methamphetamine use disorder treated with the antibiotic drug minocycline. Gen Hosp Psychiatry 2009, 32(559):e1-e3.
175. Tasdemir S, Parlakpinar H, Vardi N, Kaya E, Acet A. Effect of endogen-exogenous melatonin and erythropoietin on dinitrobenzene sulfonic acid-induced colitis. Fundam Clin Pharmacol in press. [Electronic publication ahead of print]. http://dx.doi.org/10.1111/j.1472-8206.2011.01016.x.
176. Teh C.A., Lee T.S., Kuchibhatla M., Ashley-Koch A., Macfall J., Krishnan R., et al. Bipolar disorder, brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and brain morphology. PLoS One 2012, 7:e38469.
177. Thomaes K., Dorrepaal E., Draijer N., De Ruiter M.B., Van Balkom A.J., Smit J.H., et al. Reduced anterior cingulate and orbitofrontal volumes in child abuse-related complex PTSD. J Clin Psychiatry 2010, 71:1636-1644.
178. Vane J.R., Botting R.M. The mechanism of action of aspirin. Thromb Res 2003, 110:255-258.
179. Vik-Mo A.O., Ferno J., Skrede S., Steen V.M. Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells. BMC Pharmacol 2009, 9:10.
180. Viviani B., Bartesaghi S., Corsini E., Villa P., Ghezzi P., Garau A., et al. Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor. J Neurochem 2005, 93:412-421.
181. Wakade C.G., Mahadik S.P., Waller J.L., Chiu F.C. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res 2002, 69:72-79.
182. Wang Y.P., Wu Y., Li L.Y., Zheng J., Liu R.G., Zhou J.P., et al. Aspirin-triggered lipoxin A4 attenuates LPS-induced pro-inflammatory responses by inhibiting activation of NF-kappaB and MAPKs in BV-2 microglial cells. J Neuroinflammation 2011, 8:95.
183. Wang S.P., Wang Z.H., Peng D.Y., Li S.M., Wang H., Wang X.H. Therapeutic effect of mesenchymal stem cells in rats with intracerebral hemorrhage: reduced apoptosis and enhanced neuroprotection. Mol Med Report 2012, 6:848-854.
184. Wonodi I., Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr Bull 2010, 36:211-218.
185. Wyatt R.J. Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia. Schizophr Res 1991, 5:201-202.
186. Yang M.C., Lung F.W. Neuroprotection of paliperidone on SH-SY5Y cells against beta-amyloid peptide(25-35), N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death. Psychopharmacology (Berl) 2011, 217:397-410.
187. Yoshida T., Ishikawa M., Niitsu T., Nakazato M., Watanabe H., Shiraishi T., et al. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 2012, 7:e42676.
188. Yulug B., Bakar M., Ozan E. The neuroprotective effect of olanzapine. J Neuropsychiatry Clin Neurosci 2008, 20:107-108.
189. Zhang W., Hu X., Yang W., Gao Y., Chen J. Omega-3 polyunsaturated fatty acid supplementation confers long-term neuroprotection against neonatal hypoxic-ischemic brain injury through anti-inflammatory actions. Stroke 2010, 41:2341-2347.
190. Zhang X., Xu Y., Wang J., Zhou Q., Pu S., Jiang W., et al. The effect of intrathecal administration of glial activation inhibitors on dorsal horn BDNF overexpression and hind paw mechanical allodynia in spinal nerve ligated rats. J Neural Transm 2012, 119:329-336.
191. Zhao L.R., Berra H.H., Duan W.M., Singhal S., Mehta J., Apkarian A.V., et al. Beneficial effects of hematopoietic growth factor therapy in chronic ischemic stroke in rats. Stroke 2007, 38:2804-2811.
192. Zhao L.R., Navalitloha Y., Singhal S., Mehta J., Piao C.S., Guo W.P., et al. Hematopoietic growth factors pass through the blood-brain barrier in intact rats. Exp Neurol 2007, 204:569-573.
193. Zhao L.R., Singhal S., Duan W.M., Mehta J., Kessler J.A. Brain repair by hematopoietic growth factors in a rat model of stroke. Stroke 2007, 38:2584-2591.
194. Zhong J., Lee W.H. Hydrogen peroxide attenuates insulin-like growth factor-1 neuroprotective effect, prevented by minocycline. Neurochem Int 2007, 51:398-404.
195. Zhou R., Gray N.A., Yuan P., Li X., Chen J., Chen G., et al. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci 2005, 25:4493-4502.
196. Zmarowski A., Wu H.Q., Brooks J.M., Potter M.C., Pellicciari R., Schwarcz R., et al. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur J Neurosci 2009, 29:529-538.
197. Zugno A.I., Barcelos M., Oliveira L., Canever L., Luca R.D., Fraga D.B., et al. Energy metabolism, leptin, and biochemical parameters are altered in rats subjected to the chronic administration of olanzapine. Rev Bras Psiquiatr 2012, 34:168-175.